Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Doxorubicin is a strong inducer of immunogenic cell death (ICD), but it is ineffective in P-glycoprotein (Pgp)-expressing cells. Indeed, Pgp effluxes doxorubicin and impairs the immunesensitizing functions of calreticulin (CRT), an “eat-me” signal mediating ICD. It is unknown if classical Pgp inhibitors, designed to reverse chemoresistance, may restore ICD. We addressed this question by using Pgp-expressing cancer cells, treated with Tariquidar, a clinically approved Pgp inhibitor, and R-3 compound, a N,N-bis(alkanol)amine aryl ester derivative with the same potency of Tariquidar as Pgp inhibitor. In Pgp-expressing/doxorubicin-resistant cells, Tariquidar and R-3 increased doxorubicin accumulation and toxicity, reduced Pgp activity, and increased CRT translocation and ATP and HMGB1 release. Unexpectedly, only R-3 promoted phagocytosis by dendritic cells and activation of antitumor CD8+T-lymphocytes. Although Tariquidar did not alter the amount of Pgp present on cell surface, R-3 promoted Pgp internalization and ubiquitination, disrupting its interaction with CRT. Pgp knock-out restores doxorubicin-induced ICD in MDA-MB-231/DX cells that recapitulated the phenotype of R-3-treated cells. Our work demonstrates that plasma membrane-associated Pgp prevents a complete ICD notwithstanding the release of ATP and HMGB1, and the exposure of CRT. Pharmacological compounds reducing Pgp activity and amount may act as promising chemo- and immunesensitizing agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent research has revealed substantial posttranscriptional gene regulation of ABC transporters by miRNAs, underscoring the potential utilization of novel bioengineered miRNA agents to downregulate ABC transporter expression and affect intracellular drug accumulation [101].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While various ABC transporter inhibitors have been shown to sensitize drug-resistant colon cancer cells to chemotherapy drugs in experimental models [98,99,100,101], the development of PGP as a therapeutic target for cancer in general has not been successful clinically [42].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Riganti, C., Castella, B., Kopecka, J., Campia, I., Coscia, M., Pescarmona, G., Bosia, A., Ghigo, D., & Massaia, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060975 · Cited by 50
Self-citationRetractedCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866 · cited 1×
“One of the main mechanisms involved in the resistance to doxorubicin is the presence on the cell surface of efflux proteins belonging to the ATP Binding Cassette (ABC) transporters, such as ATP Binding Cassette transporter B1 or P-glycoprotein (ABCB1/Pgp), ATP Binding Cassette transporter C1 or multidrug resistance-re…”
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Self-citationA novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800 · cited 3×
“By engaging the LDL receptor-related protein 1/CD91 receptor on DCs, the dimer CRT/ERp57 initiates the phagocytosis of dying cancer cells [6,7].”
BackgroundThree Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Palmeira, A., Sousa, E., H. Vasconcelos, M., & M. Pinto, M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167392 · Cited by 484
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Garg, A. D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R. B., Bravo-San Pedro, J. M., Breckpot, K., Brough, D., Chaurio, R., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 410
Self-citationTariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Fox, E., & Bates, S. E. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.447 · Cited by 350
Immunogenic effects of chemotherapy-induced tumor cell death
Wang, Y.-J., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 314
Riganti, C., Miraglia, E., Viarisio, D., Costamagna, C., Pescarmona, G., Ghigo, D., & Bosia, A. (2005) · Cancer Research · doi:10.1158/0008-5472.516.65.2 · Cited by 271
Self-citationDefective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
Yamazaki, T., Hannani, D., Poirier-Colame, V, Ladoire, S., Locher, C., Sistigu, A., Prada, N., Adjemian, S., Catani, J. P., Freudenberg, M., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.72 · Cited by 262
Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives
Marinello, J., Delcuratolo, M., & Capranico, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113480 · Cited by 258
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Dong, J., Qin, Z., Zhang, W.-D., Cheng, G., Yehuda, A. G., Ashby, C. R., Chen, Z.-S., Cheng, X.-D., & Qin, J.-J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100681 · Cited by 255
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., De Ruysscher, D., Tejpar, S., Vandenberghe, P., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 227
CD73-Deficient Mice Are Resistant to Carcinogenesis
Stagg, J., Beavis, P. A., Divisekera, U., Liu, M. C. P., Möller, A., Darcy, P. K., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0420 · Cited by 211
Opzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F., & Arnold, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01654 · Cited by 152
Gelsomino, G., Corsetto, P. A., Campia, I., Montorfano, G., Kopecka, J., Castella, B., Gazzano, E., Ghigo, D., Rizzo, A. M., & Riganti, C. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-137 · Cited by 123
Self-citationKim, H., Barroso, M., Samanta, R., Greenberger, L., & Sztul, E. (1997) · American Journal of Physiology · doi:10.1152/ajpcell.1997.273.2.c687 · Cited by 122
Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells
Kopecka, J., Campia, I., Jacobs, A., Frei, A. P., Ghigo, D., Wollscheid, B., & Riganti, C. (2015) · Oncotarget · doi:10.18632/oncotarget.2882 · Cited by 117
Self-citationCalreticulin in phagocytosis and cancer: opposite roles in immune response outcomes
Schcolnik‐Cabrera, A., Oldak, B., Juárez, M., Cruz-Rivera, M. Y., Flisser, A., & Mendlovic, F. (2019) · APOPTOSIS · doi:10.1007/s10495-019-01532-0 · Cited by 105
Aβ40 Reduces P-Glycoprotein at the Blood–Brain Barrier through the Ubiquitin–Proteasome Pathway
Hartz, A. M. S., Zhong, Y., Wolf, A., LeVine, H., Miller, D. S., & Bauer, B. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.0350-15.2016 · Cited by 98
Ma, Y., Adjemian, S., Yang, H., Catani, J. P. P., Hannani, D., Martins, I., Michaud, M., Kepp, O., Sukkurwala, A. Q., Vacchelli, E., et al. (2013) · OncoImmunology · doi:10.4161/onci.24568 · Cited by 95
De Boo, S., Kopecka, J., Brusa, D., Gazzano, E., Matera, L., Ghigo, D., Bosia, A., & Riganti, C. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-108 · Cited by 93
Self-citationQu, Q., & Sharom, F. J. (2002) · Biochemistry · doi:10.1021/bi0120897 · Cited by 82
An updated patent review on P-glycoprotein inhibitors (2011-2018)
Leopoldo, M., Nardulli, P., Contino, M., Leonetti, F., Luurtsema, G., & Colabufo, N. A. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1618273 · Cited by 75
Self-citationNew Therapeutic Strategies for Triple-Negative Breast Cancer.
Székely, B., Silber, A. L. M., & Pusztai, L. (2017) · PubMed · Cited by 71
Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein
Weidner, L. D., Fung, K.-L., Kannan, P., Moen, J. K., Kumar, J. S., Mulder, J., Innis, R. B., Gottesman, M. M., & Hall, M. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067785 · Cited by 70
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
Michaud, M., Sukkurwala, A. Q., Martins, I., Shen, S., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19070 · Cited by 67
Aoto, K., Mimura, K., Okayama, H., Saito, M., Chida, S., Noda, M., Nakajima, T., Saito, K., Abe, N., Ohki, S., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6097 · Cited by 67
Buondonno, I., Gazzano, E., Tavanti, E., Chegaev, K. Y., Kopecka, J., Fanelli, M., Rolando, B., Fruttero, R., Gasco, A., Hattinger, C. M., et al. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2967-9 · Cited by 65
Self-citationPumping of Drugs by P-Glycoprotein: A Two-Step Process?
Litman, T., Skovsgaard, T., & Stein, W. D. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.056960 · Cited by 63
Al-Akra, L., Bae, D.-H., Sahni, S., Huang, M. L. H., Park, K. C., Lane, D. J. R., Jansson, P. J., & Richardson, D. R. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.772699 · Cited by 54
The Role of C/EBP-β LIP in Multidrug Resistance
Riganti, C., Kopecka, J., Panada, E., Barak, S., & Rubinstein, M. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv046 · Cited by 54
Self-citationRolle, F., Bincoletto, V., Gazzano, E., Rolando, B., Lollo, G., Stella, B., Riganti, C., & Arpicco, S. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119191 · Cited by 52
Self-citationNatural modulators of the hallmarks of immunogenic cell death
Radogna, F., Dicato, M. A., & Diederich, M. F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.016 · Cited by 50
Structure–Activity Relationships of Tariquidar Analogs as Multidrug Resistance Modulators
Pajeva, I. K., & Wiese, M. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9118-z · Cited by 49
Loo, T. W., & Clarke, D. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.695171 · Cited by 48
P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors
Kopecka, J., Rankin, G. M., Salaroglio, I. C., Poulsen, S., & Riganti, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13040 · Cited by 44
Self-citationInsights in the chemical components of liposomes responsible for P-glycoprotein inhibition
Kopecka, J., Salzano, G., Campia, I., Lusa, S., Ghigo, D., Rosa, G. D., & Riganti, C. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.06.013 · Cited by 44
Self-citationWei, N., Sun, H., Wang, F., & Liu, G.-T. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1397-7 · Cited by 41
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma
Kopecka, J., Salaroglio, I. C., Righi, L., Libener, R., Orecchia, S., Grosso, F., Milosevic, V., Ananthanarayanan, P., Ricci, L., Capelletto, E., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.022 · Cited by 39
Self-citationNitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells
Kopecka, J., Campia, I., Brusa, D., Doublier, S., Matera, L., Ghigo, D., Bosìa, A., & Riganti, C. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01137.x · Cited by 35
Self-citationG-Quadruplex Binders Induce Immunogenic Cell Death Markers in Aggressive Breast Cancer Cells
Somma, S. D., Amato, J., Iaccarino, N., Pagano, B., Randazzo, A., Portella, G., & Malfitano, A. M. (2019) · Cancers · doi:10.3390/cancers11111797 · Cited by 26
Teodori, E., Contino, M., Riganti, C., Bartolucci, G., Braconi, L., Manetti, D., Romanelli, M. N., Trezza, A., Athanasios, A., Spiga, O., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111655 · Cited by 25
Self-citationTome, M. E., Schaefer, C. P., Jacobs, L. M., Zhang, Y., Herndon, J. M., Matty, F. O., & Davis, T. P. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13106 · Cited by 20
Cited by
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., De Ruysscher, D., Tejpar, S., Vandenberghe, P., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 227
Ashrafizadeh, M., Zarrabi, A., Hashemi, F., Moghadam, E. R., Hashemi, F., Entezari, M., Hushmandi, K., Mohammadinejad, R., & Najafi, M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117984 · Cited by 162
Bian, M., Fan, R., Yang, Z., Chen, Y., Xu, Z., Lu, Y., & Liu, W. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01248 · Cited by 86
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Recent research has revealed substantial posttranscriptional gene regulation of ABC transporters by miRNAs, underscoring the potential utilization of novel bioengineered miRNA agents to down-regulate ABC transporter expression and affect intracellular drug accumulation [101].”
Approaches to minimize the effects of P‐glycoprotein in drug transport: A review
Husain, A., Makadia, V., Valicherla, G. R., Riyazuddin, M., & Gayen, J. R. (2022) · Drug Development Research · doi:10.1002/ddr.21918 · Cited by 73
Metadata
- Authors
- Kopecka, J., Godel, M., Dei, S., Giampietro, R., Belisario, D. C., Akman, M., Contino, M., Teodori, E., & Riganti, C.
- Affiliations
- University of Turin (IT)
- University of Florence (IT)
- University of Bari Aldo Moro (IT)
- Corresponding author
- Riganti, Chiara
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-04-22
- Volume
- 9
- Issue
- 4
- Pages
- 1033
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7226521
- OpenAlex
- W3019388022
- Cited by
- 41
- References
- 47
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 9 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 4
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-04-22)
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (IG21408)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- P-glycoprotein inhibitors, immunogenic cell death, doxorubicin resistance, tariquidar, calreticulin, ubiquitination, dendritic cell phagocytosis, CD8+ T cells, HMGB1, ATP release, chemoresistance reversal
- MeSH terms
- Immunogenic Cell Death, Doxorubicin, Endocytosis, Esters, Humans, Kinetics, Quinolines, Apoptosis, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, Calreticulin, Cell Line, Tumor, Ubiquitination, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.